Nectar Lifesciences Past Earnings Performance
Past criteria checks 1/6
Nectar Lifesciences's earnings have been declining at an average annual rate of -35.2%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 14.3% per year. Nectar Lifesciences's return on equity is 0.8%, and it has net margins of 0.5%.
Key information
-35.2%
Earnings growth rate
-35.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -14.3% |
| Return on equity | 0.8% |
| Net Margin | 0.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nectar Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 16,322 | 81 | 829 | 0 |
| 30 Sep 23 | 15,241 | -28 | 810 | 0 |
| 30 Jun 23 | 15,148 | -263 | 797 | 0 |
| 31 Mar 23 | 15,237 | -242 | 796 | 0 |
| 31 Dec 22 | 16,120 | -162 | 789 | 0 |
| 30 Sep 22 | 17,109 | 28 | 785 | 0 |
| 30 Jun 22 | 16,868 | 272 | 749 | 0 |
| 31 Mar 22 | 16,689 | 250 | 763 | 0 |
| 31 Dec 21 | 15,421 | -276 | 857 | 0 |
| 30 Sep 21 | 14,765 | -454 | 868 | 0 |
| 30 Jun 21 | 15,387 | -546 | 742 | 0 |
| 31 Mar 21 | 15,433 | -733 | 872 | 0 |
| 31 Dec 20 | 17,586 | -249 | 765 | 0 |
| 30 Sep 20 | 20,291 | -86 | 776 | 0 |
| 30 Jun 20 | 21,807 | 12 | 804 | 0 |
| 31 Mar 20 | 23,664 | 318 | 828 | 0 |
| 31 Dec 19 | 25,973 | 419 | 814 | 0 |
| 30 Sep 19 | 26,819 | 446 | 809 | 0 |
| 30 Jun 19 | 28,274 | 480 | 798 | 0 |
| 31 Mar 19 | 27,829 | 476 | 812 | 0 |
| 31 Mar 18 | 18,763 | 523 | 798 | 0 |
| 31 Mar 17 | 16,437 | 553 | 806 | 0 |
| 31 Mar 16 | 16,757 | 542 | 832 | 0 |
| 31 Mar 15 | 16,436 | 663 | 639 | 0 |
| 31 Mar 14 | 16,383 | 621 | 938 | 0 |
Quality Earnings: 532649 has a large one-off gain of ₹405.1M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 532649 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532649's earnings have declined by 35.2% per year over the past 5 years.
Accelerating Growth: 532649 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 532649 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 532649's Return on Equity (0.8%) is considered low.